Theravance Biopharma (TBPH) Capital Expenditures (QoQ) (2013 - 2024)
Theravance Biopharma (TBPH) Capital Expenditures (QoQ) (2013 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,166.67% |
| Sep 30, 2024 | -58.33% |
| Jun 30, 2024 | -60.44% |
| Mar 31, 2024 | -86.56% |
| Dec 31, 2023 | 3,123.81% |
| Sep 30, 2023 | -97.54% |
| Jun 30, 2023 | -9.17% |
| Mar 31, 2023 | 252.63% |
| Dec 31, 2022 | 566.67% |
| Sep 30, 2022 | -150.44% |
| Jun 30, 2022 | -54.80% |
| Mar 31, 2022 | -43.69% |
| Dec 31, 2021 | -57.27% |
| Sep 30, 2021 | 566.03% |
| Jun 30, 2021 | -91.17% |
| Mar 31, 2021 | 42.04% |
| Dec 31, 2020 | -39.32% |
| Sep 30, 2020 | -13.43% |
| Jun 30, 2020 | 148.22% |
| Mar 31, 2020 | -26.78% |